The Bunkerhill BMD software provides AI-automated assessment of bone mineral density from non-contrast abdominal computed tomography scans.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the artificial intelligence (AI)-enabled Bunkerhill BMD software, which provides automated bone mineral density (BMD) assessments of non-contrast abdominal computed tomography (CT) scans.
Cleared for use in adults 30 years of age and older, the Bunkerbill BMD software offers evaluation of spinal bone structures from abdominal CT scans without the need for additional imaging hardware or radiation exposure, according to Bunkerhill Health, the distributor of the software.
The AI-powered Bunkerhill BMD software, which provides automated bone mineral density (BMD) assessments from non-contrast abdominal computed tomography (CT) scans, has garnered 510(k) clearance from the FDA. (Image courtesy of Bunkerhill Health.)
While estimates suggest that osteoporosis affects approximately 200 million worldwide, Bunkerhill Health notes that reportedly fewer than 25 percent of eligible women have BMD testing.
However, Akshay Chaudhari, M.D., who developed the software’s algorithm along with Louis Blankemeier, Ph.D., said Bunkerhill BMD can significantly enhance opportunistic screening and facilitate preventative measures for patients at risk for osteoporosis.
“The ability to assess bone health without additional scans, radiation exposure to patients, and cumbersome manual analysis needed from radiologists represents a paradigm shift in how we think about preventative care,” noted Dr. Chaudhari, an assistant professor of radiology and biomedical data science at Stanford University and co-director of clinical AI at Stanford Radiology. “This algorithm reflects how academic innovation, when paired with thoughtful product development, can deliver tools that are both impactful and scalable.”
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
Photon-Counting Computed Tomography: Eleven Takeaways from a New Literature Review
May 27th 2025In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.